<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982030</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00054355</org_study_id>
    <nct_id>NCT03982030</nct_id>
  </id_info>
  <brief_title>Dalbavancin Outpatient Pilot</brief_title>
  <official_title>An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine if a new antibiotic called dalbavancin will work
      to treat and cure certain infections while reducing the need for daily antibiotics by vein.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 4, single-center, pilot open-label trial assessing the safety and efficacy of
      dalbavancin in the outpatient therapy of susceptible gram-positive infections requiring
      prolonged intravenous therapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with resolution of infection</measure>
    <time_frame>Week 6</time_frame>
    <description>Number of participants with no recurrent signs or symptom of infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with development of breakthrough infection - week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Number of participants with worsening signs or symptoms of primary infection or development of new infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with development of breakthrough infection - Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of participants with worsening signs or symptoms of primary infection or development of new infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with hospital readmission - week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Number of participants readmitted for the primary infection under treatment or related complication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with hospital readmission - Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of participants readmitted for the primary infection under treatment or related complication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with need for further surgical intervention - week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Number of participants that need surgical intervention for primary infection prior to end of study participation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with need for further surgical intervention - Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of participants that need surgical intervention for primary infection prior to end of study participation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events leading to discontinuation of study drug -week 6</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events leading to discontinuation of study drug - Month 6</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants loss to follow-up - week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Number of participants that fail to receive second planned dalbavacin dose and attend study visits.
failure to attend scheduled visits after receiving second dalbavancin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants loss to follow-up - Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of participants that fail to receive second planned dalbavacin dose and attend study visits.
failure to attend scheduled visits after receiving second dalbavancin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of antibiotic therapy</measure>
    <time_frame>Month 6</time_frame>
    <description>Costs of antibiotic therapy will be measured by combined estimated total costs per participant of inpatient and outpatient antibiotic therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Study Questionnaire week 4</measure>
    <time_frame>week 4</time_frame>
    <description>Participant satisfaction will be measured using the 5 point scale (4-strongly agree, 3-agree, 2 neutral, 1-disagree, and 0-strongly disagree). Higher scores denote better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Study Questionnaire week 24</measure>
    <time_frame>Month 6</time_frame>
    <description>Participant satisfaction will be measured using the 5 point scale (4-strongly agree, 3-agree, 2 neutral, 1-disagree, and 0-strongly disagree). Higher scores denote better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with reported overdose</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with new enrollment in addiction treatment</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants re-admitted for addiction-related issue</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time investment per patient required to follow this model</measure>
    <time_frame>6 months</time_frame>
    <description>Time investment per patient will be measured by combined time in minutes spent by study and clinical staff on addiction-related phone calls, paperwork and in-person appointments.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Gram-Positive Bacterial Infections</condition>
  <condition>Soft Tissue Infections</condition>
  <arm_group>
    <arm_group_label>Dalbavancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with susceptible gram-positive infections requiring prolonged parenteral antibiotic therapy will be treated with dalbavancin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalbavancin</intervention_name>
    <description>Dalbavancin 1.5g IV at day 0, day 8-10</description>
    <arm_group_label>Dalbavancin</arm_group_label>
    <other_name>Dalvance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  &gt;=18 years of age

          -  Provide informed consent

          -  Agreement to attend required follow-up visits with reasonable transportation plan

          -  Afebrile for at least 24 hours prior to enrollment

          -  Expected survival â‰¥3 months

          -  If female, non-pregnant and non-lactating; all females of child-bearing potential must
             have a negative pregnancy test prior to study entry and must agree to use a highly
             effective method of birth control during the study and for one month thereafter.

          -  Anticipated hospital discharge within 8 days

          -  Joint and bone infection:

          -  Sterile site culture positive for susceptible organism

          -  Participants with bacteremia and right-sided infective endocarditis (IE):

               -  2 or more blood cultures positive for S. aureus (MSSA or MRSA or Streptococci)

               -  Blood cultures negative for 72 hours within 7 days on standard of care antibiotic
                  therapy

               -  Definite diagnosis of right sided infective endocarditis by Duke Criteria

               -  Echocardiographic assessment (TTE or TEE)

          -  For patients with opioid use disorder and history of injection opioid use,

               -  Injection of opioid substances (IOS) in the last 6 months

               -  Fulfill criteria for opioid use disorder

        Exclusion

          -  Polymicrobial infection

          -  Baseline QTc &gt;500 msec

          -  Creatinine clearance &lt;30 mL per min

          -  Immunocompromised from neutropenia, AIDS, malignancy, chemotherapy, or receiving
             immunosuppressant medication including systemic corticosteroids (intranasal or inhaled
             corticosteroids acceptable)

          -  Patients with documented allergies to lipoglycopeptides, vancomycin, or teicoplanin

          -  Concurrent diseases that, in the Investigator's medical judgment, would interfere with
             the conduct of the study, confound the interpretation of the study results, or
             endanger the patient's well-being

          -  For participants with right-sided IE:

          -  No mitral or aortic valve involvement on echocardiogram

          -  Large, mobile vegetations (&gt;10mm)

          -  Perivalvular abscess

          -  Presence of an intracardiac device (defibrillator or pacer) or prosthetic valve
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caryn Morse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caryn G Morse, MD</last_name>
    <phone>(336) 716-2700</phone>
    <email>cmorse@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Barnes, MD</last_name>
    <phone>(336) 716-2700</phone>
    <email>ebarnes@wakehealth.edu</email>
  </overall_contact_backup>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dalbavacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Soft Tissue Infections</mesh_term>
    <mesh_term>Gram-Positive Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalbavancin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

